Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate
Journal Publication ResearchOnline@JCUAbstract
Streptococcus pyogenes (group A streptococcus, GAS) causes a wide range of clinical manifestations ranging from mild self-limiting pyoderma to invasive diseases such as sepsis. Also of concern are the post-infectious immune-mediated diseases including rheumatic heart disease. The development of a vaccine against GAS would have a large health impact on populations at risk of these diseases. However, there is a lack of suitable models for the safety evaluation of vaccines with respect to post-infectious complications. We have utilized the Lewis Rat model for cardiac valvulitis to evaluate the safety of the J8-DT vaccine formulation in parallel with a rabbit toxicology study. These studies demonstrated that the vaccine did not induce abnormal pathology. We also show that in mice the vaccine is highly immunogenic but that 3 doses are required to induce protection from a GAS skin challenge even though 2 doses are sufficient to induce a high antibody titer.
Journal
Human Vaccines & Immunotherapeutics
Publication Name
N/A
Volume
12
ISBN/ISSN
2164-554X
Edition
N/A
Issue
12
Pages Count
8
Location
N/A
Publisher
Landes Bioscience
Publisher Url
N/A
Publisher Location
N/A
Publish Date
N/A
Url
N/A
Date
N/A
EISSN
N/A
DOI
10.1080/21645515.2016.1222999